Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MPA.0000000000000308 http://scihub22266oqcxt.onion/10.1097/MPA.0000000000000308 C4399019!4399019!25875801     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pancreas 2015 ; 44 (4): 636-47 Nephropedia Template TP {{tp|p=25875801|t=2015. Metformin suppresses pancreatic tumor growth with inhibition of NF?B/STAT3 inflammatory signaling |pdf=|usr=}}{{25875801}} gab.com Text Metformin suppresses pancreatic tumor growth with inhibition of NF B/STAT3 inflammatory signaling JO: Pancreas http://www.kidney.de/pget.php?&tw=1&pmid=25875801 #FOAvip Objectives: To further elucidate anti-cancer mechanisms of metformin again pancreatic cancer, we evaluated inhibitory effects of metformin on pancreatic tumorigenesis in a genetically-engineered mouse model, and investigated its possible anti-inflammatory and anti-angiogenesis effects. Methods: Six-week old LSL-KrasG12D/+;Trp53F2-10 mice (10 per group) were administered once daily intraperitoneally with saline (control) for one week or metformin (125 mg/kg) for one week (Met_1wk) or three weeks (Met_3wk) prior to tumor initiation. All mice continued with their respective injections for six weeks post-tumor initiation. Molecular changes were evaluated by quantitative polymerase chain reaction (PCR), immunohistochemistry, and Western blotting. Results: At euthanasia, pancreatic tumor volume in Met_1wk (median, 181.8 mm3) and Met_3wk (median, 137.9 mm3) groups was significantly lower than the control group (median, 481.1 mm3) (P = 0.001 and 0.0009, respectively). No significant difference was observed between Met_1wk and Met_3wk groups (P = 0.51). These results were further confirmed using tumor weight and tumor burden measurements. Furthermore, metformin treatment decreased the phosphorylation of nuclear factor ?B (NF?B) and signal transducer and activator of transcription 3 (STAT3) as well as the expression of Sp1 transcription factor and several NF?B-regulated genes. Conclusions: Metformin may inhibit pancreatic tumorigenesis by modulating multiple molecular targets in inflammatory pathways. Twit Text FOAVip Metformin suppresses pancreatic tumor growth with inhibition of NF B/STAT3 inflammatory signaling ????Pancreas http://www.kidney.de/pget.php?&tw=1&pmid=25875801 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25875801 #FOAvip English Wikipedia <ref>{{Cite pmid|25875801}}</ref> Metformin suppresses pancreatic tumor growth with inhibition of NF?B/STAT3 inflammatory signaling #MMPMID25875801 Tan XL; Bhattacharyya KK; Dutta SK; Bamlet WR; Rabe KG; Wang E; Smyrk TC; Oberg AL; Petersen GM; Mukhopadhyay D Pancreas 2015[May]; 44 (4): 636-47 PMID25875801show ga Objectives: To further elucidate anti-cancer mechanisms of metformin again pancreatic cancer, we evaluated inhibitory effects of metformin on pancreatic tumorigenesis in a genetically-engineered mouse model, and investigated its possible anti-inflammatory and anti-angiogenesis effects. Methods: Six-week old LSL-KrasG12D/+;Trp53F2-10 mice (10 per group) were administered once daily intraperitoneally with saline (control) for one week or metformin (125 mg/kg) for one week (Met_1wk) or three weeks (Met_3wk) prior to tumor initiation. All mice continued with their respective injections for six weeks post-tumor initiation. Molecular changes were evaluated by quantitative polymerase chain reaction (PCR), immunohistochemistry, and Western blotting. Results: At euthanasia, pancreatic tumor volume in Met_1wk (median, 181.8 mm3) and Met_3wk (median, 137.9 mm3) groups was significantly lower than the control group (median, 481.1 mm3) (P = 0.001 and 0.0009, respectively). No significant difference was observed between Met_1wk and Met_3wk groups (P = 0.51). These results were further confirmed using tumor weight and tumor burden measurements. Furthermore, metformin treatment decreased the phosphorylation of nuclear factor ?B (NF?B) and signal transducer and activator of transcription 3 (STAT3) as well as the expression of Sp1 transcription factor and several NF?B-regulated genes. Conclusions: Metformin may inhibit pancreatic tumorigenesis by modulating multiple molecular targets in inflammatory pathways. äMetformin suppresses pancreatic tumor growth with inhibition of NF?B/S(epmc).pdf DeepDyve Pubget Overpricing